Abstract
Introduction: We evaluated baseline itch and its impact on the efficacy of ixekizumab (IXE) in clearing psoriasis and improving quality-of-life measures, and we explored the relationship between itch and psoriatic skin improvement. Methods: Data were analyzed from two double-blind, randomized, controlled phase III studies (UNCOVER-2/3) comparing etanercept (ETN), IXE, and placebo (PBO) in patients with moderate-to-severe plaque psoriasis. Long-term analysis included UNCOVER-3 data from week 0 to week 156. Results: At week 12, a clinically meaningful improvement in itch [Itch Numeric Rating Scale (NRS) reduction ≥ 4] was seen in 70.0%, 88.6%, and 90.8% of the IXE-treated patients in the baseline Itch NRS 4–6, 7–8, and 9–10 groups, respectively (all itch severity groups p < 0.001 versus ETN and PBO). Also, 68.9%, 67.1%, and 73.6% of the IXE-treated patients in the baseline Itch NRS 4–6, 7–8, and 9–10 groups, respectively, showed an improvement of ≥ 90.0% in the Psoriatic Area and Severity Index (PASI) at week 12 as compared to the baseline (PASI 90) (all itch severity groups p < 0.001 versus ETN and PBO). For most patients, itch reduction preceded psoriatic plaque improvement. Sustained effects of IXE on itch and PASI were observed during 3 years of treatment. Conclusions: Regardless of baseline itch severity, IXE treatment provided a rapid improvement in itch followed by clinically meaningful improvements in psoriasis. Funding: Eli Lilly and Company. Trial registration: ClinicalTrials.gov identifiers, NCT01597245 and NCT01646177.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 621-637 |
| Number of pages | 17 |
| Journal | Dermatology and Therapy |
| Volume | 8 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 1 2018 |
Fingerprint
Keywords
- IL-17A
- Itch
- Ixekizumab
- Psoriasis
ASJC Scopus subject areas
- Dermatology
Cite this
Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis : An Integrated Analysis of Two Phase III Randomized Studies. / Yosipovitch, Gil; Reich, Adam; Steinhoff, Martin; Beselin, Anke; Kent, Toby; Dossenbach, Martin; Berggren, Lovisa; Henneges, Carsten; Luger, Thomas.
In: Dermatology and Therapy, Vol. 8, No. 4, 01.12.2018, p. 621-637.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis
T2 - An Integrated Analysis of Two Phase III Randomized Studies
AU - Yosipovitch, Gil
AU - Reich, Adam
AU - Steinhoff, Martin
AU - Beselin, Anke
AU - Kent, Toby
AU - Dossenbach, Martin
AU - Berggren, Lovisa
AU - Henneges, Carsten
AU - Luger, Thomas
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Introduction: We evaluated baseline itch and its impact on the efficacy of ixekizumab (IXE) in clearing psoriasis and improving quality-of-life measures, and we explored the relationship between itch and psoriatic skin improvement. Methods: Data were analyzed from two double-blind, randomized, controlled phase III studies (UNCOVER-2/3) comparing etanercept (ETN), IXE, and placebo (PBO) in patients with moderate-to-severe plaque psoriasis. Long-term analysis included UNCOVER-3 data from week 0 to week 156. Results: At week 12, a clinically meaningful improvement in itch [Itch Numeric Rating Scale (NRS) reduction ≥ 4] was seen in 70.0%, 88.6%, and 90.8% of the IXE-treated patients in the baseline Itch NRS 4–6, 7–8, and 9–10 groups, respectively (all itch severity groups p < 0.001 versus ETN and PBO). Also, 68.9%, 67.1%, and 73.6% of the IXE-treated patients in the baseline Itch NRS 4–6, 7–8, and 9–10 groups, respectively, showed an improvement of ≥ 90.0% in the Psoriatic Area and Severity Index (PASI) at week 12 as compared to the baseline (PASI 90) (all itch severity groups p < 0.001 versus ETN and PBO). For most patients, itch reduction preceded psoriatic plaque improvement. Sustained effects of IXE on itch and PASI were observed during 3 years of treatment. Conclusions: Regardless of baseline itch severity, IXE treatment provided a rapid improvement in itch followed by clinically meaningful improvements in psoriasis. Funding: Eli Lilly and Company. Trial registration: ClinicalTrials.gov identifiers, NCT01597245 and NCT01646177.
AB - Introduction: We evaluated baseline itch and its impact on the efficacy of ixekizumab (IXE) in clearing psoriasis and improving quality-of-life measures, and we explored the relationship between itch and psoriatic skin improvement. Methods: Data were analyzed from two double-blind, randomized, controlled phase III studies (UNCOVER-2/3) comparing etanercept (ETN), IXE, and placebo (PBO) in patients with moderate-to-severe plaque psoriasis. Long-term analysis included UNCOVER-3 data from week 0 to week 156. Results: At week 12, a clinically meaningful improvement in itch [Itch Numeric Rating Scale (NRS) reduction ≥ 4] was seen in 70.0%, 88.6%, and 90.8% of the IXE-treated patients in the baseline Itch NRS 4–6, 7–8, and 9–10 groups, respectively (all itch severity groups p < 0.001 versus ETN and PBO). Also, 68.9%, 67.1%, and 73.6% of the IXE-treated patients in the baseline Itch NRS 4–6, 7–8, and 9–10 groups, respectively, showed an improvement of ≥ 90.0% in the Psoriatic Area and Severity Index (PASI) at week 12 as compared to the baseline (PASI 90) (all itch severity groups p < 0.001 versus ETN and PBO). For most patients, itch reduction preceded psoriatic plaque improvement. Sustained effects of IXE on itch and PASI were observed during 3 years of treatment. Conclusions: Regardless of baseline itch severity, IXE treatment provided a rapid improvement in itch followed by clinically meaningful improvements in psoriasis. Funding: Eli Lilly and Company. Trial registration: ClinicalTrials.gov identifiers, NCT01597245 and NCT01646177.
KW - IL-17A
KW - Itch
KW - Ixekizumab
KW - Psoriasis
UR - http://www.scopus.com/inward/record.url?scp=85057288267&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057288267&partnerID=8YFLogxK
U2 - 10.1007/s13555-018-0267-9
DO - 10.1007/s13555-018-0267-9
M3 - Article
AN - SCOPUS:85057288267
VL - 8
SP - 621
EP - 637
JO - Dermatology and Therapy
JF - Dermatology and Therapy
SN - 2190-9172
IS - 4
ER -